ReviewMedComm2026
RNA Regulatory Networks: Key Hubs in the Panorama of Cancer and Emerging Therapeutic Targets.
Review in MedComm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Non-coding RNA networks in metabolic dysfunction-associated steatotic liver disease: Mechanisms and therapeutic perspectives.Liver research (Beijing, China) · 2026Review
- The TMPO-AS1/hsa-let-7b-5p regulatory axis shapes transcriptional heterogeneity and immune landscape in lung adenocarcinoma.Cell division · 2026Article
- Review
- Novel Indazole Compounds as PKMYT1 Kinase Inhibitors for Treating Cancer.ACS medicinal chemistry letters · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is a global health challenge. The initiation and progression of cancer are correlated with dynamic dysregulation of RNA regulatory networks. This review systematically explains how contending RNAs (including mRNA, miRNA, lncRNA, circRNA, etc.) remold gene expression programs across multiple dimensions. They do this primarily through the competing endogenous RNA sponge effect, RNA-protein complex assembly, RNA editing (A-to-I editing, m6A modification, etc.), tumorigenesis, heterogeneous evolution, and therapeutic resistance. RNA regulatory networks do not only help one to decode cancer biology but because they are dynamic in nature, they are now also being looked at as good precision targets for diagnosis and treatment. This article integrates recent findings on the emerging functions of RNA networks in tumor metabolic reprogramming, tumor immune microenvironment shaping, and cancer stem cell property maintenance, while highlighting their clinical application prospects as liquid biopsy biomarkers. Our therapies focus on assessing the potential and clinical translation bottlenecks of novel RNA-targeted interventions, including antisense oligonucleotides, RNA aptamers, and the CRISPR-Cas13 system. A dynamic adjustability made the RNA-targeted therapies promising intervention nodes in precision medicine even if most of them are still in a preclinical state.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.